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Summary The chemosensitising effect of the nitroaromatic radiosensitiser misonidazole (MISO) on the
alkylating agent cyclophosphamide (CTX) has been investigated in a C3H mammary carcinoma in CDF, mice.
The selective cytotoxicity against aerobic and hypoxic cells was measured indirectly, using a local tumour
control (TCD50) assay. The hypoxic fraction was calculated from the dose difference between the TCD50s for
tumours irradiated either in air or under clamped conditions. The relative survival of tumour cells after drug
therapy was expressed as a surviving fraction (SF). CTX (100 mgkg-) was found to be considerably more
toxic towards hypoxic than aerobic cells (SF 4% versus 52%). MISO (1000mgkg-) was almost exclusively
toxic to hypoxic cells (SF 22%). When MISO and CTX were administered simultaneously a decrease in the
surviving fraction was observed. The effect on aerated cells was found to be 10-fold more than expected from
addition of toxicities, suggesting a chemosensitising effect on these cells by MISO when used in combination
with CTX. No synergistic effect was found on radiobiologically hypoxic cells. The exact role of hypoxia for
the development of chemosensitisation seems to be complex and requires additional research in the future.
The ability of nitroimidazoles to enhance the tumour res-
ponse of anti-cancer drugs has been shown by several inves-
tigators in different animal models (see review by Siemann,
1982) and is currently being investigated in phase II clinical
trials. However, the mechanisms underlying the observed
chemosensitisation in vivo is still not settled, although several
suggestions have been made. These include the preferential
killing of hypoxic cells by the nitroimidazole, changes in the
pharmacokinetics and metabolism of the cancer
chemotherapeutic drug, interference with the repair of poten-
tially lethal damage and a manifestation of the in vitro
pre-incubation effect observed under hypoxic conditions
(Brown, 1982; Siemann, 1982, 1984). In vitro, hypoxia has
been found to be a prerequisite for chemopotentiation to
occur. No effect has been observed if cells were exposed to
the sensitiser under aerobic conditions, unless extremely high
doses were used (Smith et al., 1982). Some studies in vivo
have also suggested that hypoxia plays a role in the develop-
ment of chemosensitisation. The observation is primarily
based on a relationship between the amount of sensitisation
observed and the degree of tumour hypoxia (Siemann, 1984;
Wheeler et al., 1984). However, the observed sensitisation
generally exceeds what would be expected if the interaction
between the sensitiser and the drug was restricted to the
radiobiologically hypoxic tumour cell population (Brown &
Hirst, 1982; Hinchliffe et al., 1983; Horsman et al., 1984).
Thus the importance of hypoxic conditions for chemosen-
sitisation in vivo is still unsettled.
The aim of the present study was to investigate the selec-
tive effect of MISO and the alkylating agent cyclophos-
phamide (CTX) on aerobic and hypoxic cells in situ, using a
clamped local tumour control assay applied to a C3H mouse
mammary carcinoma.
Materials and methods
Animal tumour system
The C3H/Tif mammary carcinoma was grown in the right
rear foot of 10-12-week-old male C3D2F1 mice. Non-
anaesthetised mice were treated when tumours were on
average 200 mm3 (in the range 150-257 mm3), determined by
the formula: n/6 x Dl x D2 x D3, where the Ds represent the
three orthogonal diameters.
Irradiation
Irradiation was given as single doses with 250 kV X-rays
(lOmA, HVL 3.1 mm Cu, dose rate 2.26Gymin-'). The
mice were placed in a lucite jig with the tumour-bearing leg
exposed, loosely taped to the jig and immersed in a water
bath to ensure a homogeneous dose distribution in the
tumour. Animals receiving X-rays under hypoxic conditions
had the tumour-bearing leg clamped 5 min before and during
the period of irradiation. Clamping was achieved by constric-
tion of the blood flow using a rubber tube tightened around
the leg. The validity of this procedure to generate complete
radiobiological hypoxia has been documented previously
(Grau & Overgaard, 1988).
Drugs
MISO was dissolved in isotonic saline at room temperature
and administered intraperitoneally (i.p.) in a volume of
0.04 ml g-' body weight. CTX was dissolved in sterile dis-
tilled water and injected i.p. at a volume of 0.02 ml g-' body
weight. MISO was given 4 h after irradiation, followed by
CTX 15 min later.
Tumour growth delay
The tumour volume was measured daily and the response
evaluated in terms of tumour growth time (TGT), defined as
the time required for a tumour to reach three times treatment
volume. The exponential regrowth phase was used to cal-
culate the volume doubling time (DT). All calculations were
based on individual growth data.
Local tumour control
The effect of graded doses of radiation alone or in combina-
tion with drugs was evaluated as the radiation dose required
to produce local tumour control in 50% of the treated
animals (TCD50). Tumour control was defined as complete
absence of macroscopic relapse within 90 days. Data were
analysed using a Logit analysis (Suit et al., 1965).
Hypoxicfraction
The proportion of radiobiologically hypoxic tumour cells, the
hypoxic fraction (HF), was calculated from the local tumour
control data as described in the Appendix. The validity of the
biological assumptions underlying these formulae have been
discussed in details in a previous paper (Grau & Overgaard,
1988). In short, the HF was calculated from the horizontal
distance between TCD^o curves for tumours irradiated under
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aerobic or clamped conditions and the D. for hypoxic cells.
The total number of tumour cells (N) was calculated from
the TCD50 values, as also described in the Appendix. Based
on drug-induced changes in HF and N, the surviving fraction
(SF) of aerobic and hypoxic cells was calculated. Statistical
analysis was done by the propagation-of-error technique.
Results
The influence of the clamping procedure on drug access and
toxicity was tested in a tumour regrowth delay study (Table
I). The response of tumours being clamped for a period of 30
minutes, four hours prior to drug therapy, was not
significantly different from the response of non-clamped
tumours (Student's t test, 5% significance level).
The observed TCD50 values and the calculated values for
HF and SF are presented in Table II. The TCD50 for radia-
tion alone under clamped conditions was 64.16 Gy. Assum-
ing an Do = 3.2 Gy for hypoxic cells, the total number of
clonogenic cells in the on average 200 mm3 tumour was
calculated to be 1.18 x 108. From the horizontal displacement
between the dose response curves for radiation alone (Figure
1, top left) it was estimated that the tumour contained 4.8%
(5.6 x 106) radiobiologically hypoxic cells. This value
represented the HF of untreated tumours, as the irradiation
was used only to measure the degree of hypoxia.
When tumours were treated with MISO the relative pro-
portion of hypoxic cells declined from 4.8% to 1.3%. This
reduction was statistically significant (P<0.01). CTX had a
similar effect, the HF being reduced to 0.4% (P<0.001). The
two drugs given in combination with a 15 min interval
resulted in a HF in between the values for single treatments
(1.0%; P<0.01).
The alterations in HF reflected the relative changes in the
survival of both aerobic and hypoxic cells. To evaluate fur-
ther the specific cytotoxicity of MISO and CTX, the changes
in the absolute number of surviving clonogenic cells were
calculated. The total number of aerobic cells in untreated
tumours was 1.12 x 108. The proportion of aerobic cells
which survived a given treatment was 80% for MISO and
52% for CTX. In contrast to this relatively minor effect of
the single agents on aerobic cells, the combined treatment
with MISO and CTX killed almost all aerobic cells (SF 4%).
The proportion of hypoxic cells which survived a given drug
treatment was 22% for MISO and 4% for CTX. The com-
bined treatment resulted in a SF of 1%. The magnitude of
this effect was found to be consistent with an additive cell
killing by the two drugs (22% x 4% = 1%).
Discussion
The clamped local tumour control assay used in this study
allowed quantification of the selective drug cytotoxicity
against aerobic and hypoxic tumour cells in vivo. MISO as a
single agent was found to be preferentially cytotoxic towards
hypoxic cells, a finding which is accordance with other
reports using in vitro assays (Moore et al., 1976; Sutherland
et al., 1982). CTX was found to be more toxic towards
hypoxic than aerobic cells, as previously reported from our
laboratory (Grau & Overgaard, 1988). When MISO was
added to the CTX treatment the number of surviving
hypoxic cells decreased in an additive way. For aerobic cells,
however, a marked decrease in surviving cells was observed,
which exceeded what would be predicted from the results of
the single drug treatments. Thus, if the cytotoxic effect of the
individual agents were acting independently on aerobic cells,
the expected aerobic SF, based on additive cell kill would be
42% (80% x 52%) compared to the observed survival of
4%. This 10-fold decrease in relative cell survival, although
not statistically significant, suggested a synergistic, chemosen-
sitising effect on aerobic cells. The suggestion is supported by
the results obtained when the same drug schedule was
evaluated by different end-points (Grau et al., 1990). From
tumour regrowth delay data a significant supra-additive drug
effect was found. This might reflect an enhanced effect on
aerobic cells, since oxygenated cells are believed to dominate
the overall tumour growth. On the other hand the drug-
induced modification of radiation response (in terms of local
tumour control) was purely additive, suggesting that there
was no synergistic effect on radioresistant hypoxic cells.
Although the exact mechanism is still unsettled, the
presence of hypoxia has been suggested to be critical for the
Table I Effect of 30 min ofclamping on the volume doubling time and tumour growth time
Days to reach 3 times treatment
Volume doubling time volume (TGT)
Treatment No. ofmice days t testa Observed TGT t testa
Untreated control 11 2.6(2.2-3.0) 3.5 (3.1-3.9) Clamp-30 min 8 2.6(2.4-2.8) n.s. 4.0(3.6-4.4) n.s. MISO 23 2.9 (2.5-3.3) 4.5(4.1-4.9) Clamp - 4h - MISO 13 2.8 (2.7-2.9) n.s. 4.9(4.3-5.5) n.s.
CTX 10 3.6(3.2-4.0) 13.2(9.2-17.2) Clamp - 4h - CTX 21 3.4(3.0-3.8) n.s. 13.8 (11.8-15.8) n.s. MISO-15min-CTX 9 3.7 (3.1-4.3) 22.7(18.1-27.3) Clamp-4h-MISO- 15min-CTX 6 3.5 (3.3-3.7) n.s. 22.0(20.4-23.6) n.s.
MISO 1,000 mg kg-'; CTX 100 mg kg-'. Numbers in brackets are 95% confidence interval on mean. All calculations were based on individual growth curves. aStudent's t test; clamped tumours versus non-clamped tumours. 5% significance level.
Table II Effect ofmisonidazole and cyclophosphamide on the hypoxic fraction and the survival ofaerobic and hypoxic cells in a C3H mammary carcinoma measured using a clamped local tumour control assay in vivo
Aerobic cells Hypoxic cells
No. of TCD50 air No. of TCD50 clamp Hypoxic Total Treatment mice (Gy) mice (Gy) fraction no. x 106 SFa Total no. x 103 SFa
Radiation 542 54.42 240 64.16 4.8% 112 100% 5,615 100% (53.97-54.88) (63.57-64.76) (3.7-5.9%) (90-134) (4,825-6,404) Rad-4h-MISO 168 49.51 120 63.35 1.3% 90 80% 1,210 22% (48.83-50.19) (62.34-64.37) (0.8-1.8%) (61-119) (50-110%) (953-1,468) (16-27%) Rad-4h-CTX 87 44.47 50 61.94 0.4% 59 52% 251 4% (43.55-45.40) (60.45-63.48) (0.2-0.7%) (31-86) (26-79%) (179-323) (3-6%) Rad-4h-MISO- 127 38.98 76 53.67 1.0% 4 4% 45 0.8% l5min-CTX (38.04-39.95) (52.16-55.22) (0.5-1.6%) (2-6) (2-6%) (32-58) (0.5-1.0%)
'Surviving fraction (seeAppendix). Thedrugdoseswere: MISO, 1000 mgkg-'; CTX, 100mgkg-'. Numbers inparentheses arevalue + standard error.MISONIDAZOLE AND CYCLOPHOSPHAMIDE in vivo 63
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Figure 1 TCD50 curves showing the response of C3H mammary tumours to irradiation alone or irradiation plus drug treatment
4 h later. Open circles represent the tumour response of mice irradiated in air. Filled symbols represent the response of hypoxic
(clamped) tumours. Each data point represents the response of 5-86 mice.
development of chemosensitisation observed in vitro
(Siemann, 1984). Until now no direct evidence for this
requirement of hypoxia in vivo has been presented. Some
indirect evidence exists, suggesting that hypoxia plays a role.
Tumours with small hypoxic fractions show less enhanced
damage to drugs than do the same tumours with larger
hypoxic fractions. (Martin et al., 1981; Sheldon & Batten,
1982; Spooner et al., 1982). Tumours that lack radio-
biologically hypoxic cells show no chemopotentiation unless
they are made artifically hypoxic between MISO injection
and treatment with BCNU (Wheeler et al., 1984). However,
the observed sensitisation exceeds what would be expected if
the interaction between MISO and alkylating drugs is
restricted to the small fraction of clonogenic and
radiobiologically hypoxic tumour cells (Brown & Hirst, 1982;
Hinchliffe et al., 1983; Horsman et al., 1984). So, while
hypoxia appears to be necessary for the chemosensitisation to
occur, significant effects can be seen in cells at oxygenation
levels above what would render them radiobiologically
hypoxic. This has been demonstrated by several investigators.
Durand and Chaplin (1987) used the fluorochrome
Hoechst 33342 to separate tumour cells in fractions as a
function of distance from the blood vessels. They found that
the chemosensitisation by MISO in KHT tumours treated
wth CCNU was almost constant throughout the tumour,
irrespective of the oxygenation status of the cells. In vitro the
dependence of chemosensitisation by MISO on oxygen con-
centration has been examined (Mulcahy, 1984; Roizin-Towle
et al., 1986). It was found that the Km value, defined as the
oxygen tension needed to generate half the maximum sen-
sitisation was 400 p.p.m. Horsman et al. in a recently con-
ducted study in EMT6 spheroids found constant chemosen-
sitisation by MISO to melphalan as a function of depth
within the spheroid. The binding of 4C-MISO, on the other
hand, was found to increase with depth in the spheroid.
Their data indicated that the majority of viable clonogenic
spheroid cells (which were equally chemosensitised) were at
oxygen tensions intermediate between those found in either
aerobic or radiobiologically hypoxic cells (Horsman et al.,
1989). The observations from these in vitro studies are consis-
tent with the in situ tumour data presented here, as some
sensitisation of cells in the aerobic compartment seemed to
occur. In our rather simplistic model this compartment con-
tained all cells that were not radiobiologically hypoxic at the
time of investigation.
In conclusion, this paper has presented in situ data on the
chemosensitising effect of MISO on the response of solid
tumour cells to CTX. Using a clamped tumour control assay
it was found that the addition of MISO to CTX treatment
caused a decrease in aerobic cell survival, which was 10-fold
more than what was expected on an additive basis. In con-
trast to what has been observed in vitro, no synergistic effect
was found on radiobiologically hypoxic cells. The exact role
of hypoxia for the development of chemosensitisation seems
to be complex and requires additional research in the future.
Appendix: statistical methods
This appendix contains the equations used for estimating
biological parameters and the standard errors of these.
Biological assumptions
Naturally and artifically hypoxic cells were assumed to have
identical dose-survival curves (Howes, 1969), described by the
multi-hit cell-survival model with identical extrapolation
number, n, and slope of the log-linear part of the survival
curve, Do. D. was taken to be 3.2 Gy (Suit et al., 1965). The
two types of cells were assumed to have the same biological
properties if they survived treatment, e.g. the same potential
for producing a tumour recurrence.
Statistical assumptions
Standard errors of parameter estimates were obtained using
the propagation-of-error technique. The dose required to
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control 50% of the tumours under oxic, TCD50air, or
clamped, TCD50clamp, conditions was estimated by fitting a
logit dose-response curve to the observed data. TCD50 was
assumed to have a normal distribution with standard error of
the estimate calculated from the variance-covariance matrix.
This assumption was found to be reasonable by Bentzen et
al. (1988) using Monte Carlo simulations of dose-response
data sets similar to those of the present study. Approximate
95% confidence limits may be calculated as the parameter
estimate ± 1.96 (s.e.).
Assuming the tumour control probability to be determined
solely from the radiosensitivity of the hypoxic tumour
clonogens, the number of hypoxic tumour clonogens, Nh, is
estimated as:
Nh = exp(TCD50air/D0) 1n(2)/3 (Ia)
The factor 1n(2)/3 is exp(ln(1n(2)) - In(n)) in the derivation
by Suit et al. (1965), assuming the extrapolation number n in
the multi-hit cell-survival model to be equal to 3.
The standard error of Nh may be estimated by:
s.e.(Nh) = Nh I/DO s.e.(TCD50air) (Ib)
The total number of cells, N, is estimated from the TCD50
under clamped conditions, when all clonogens are supposed
to be hypoxic:
N, = exp(TCD50clamp/D0) 1n(2)/3 (2a)
with standard error
s.e.(N,) = Nt-1I/DO s.e.(TCD50clamp) (2b)
Dividing Nh with N, (eqns la and 2a) yields the following
expression for the hypoxic fraction:
HF = exp(TCD50air/D0)/exp(TCD50clamp/D.)
= exp((TCD50air- TCD50clamp)/D.) (3a)
The standard error of HF is estimated by:
s.e.(HF) = HF I/DO [s.e.(TCD50air)2 +s.e.(TCD50clamp)1"/2 (3b)
The number of aerobic cells, Na:
Na= Nt-Nh (4a)
and
s.e.(Na) = [s.e.(Nt)2 + s.e.(Nh)2]'/' (4b)
Finally, the surviving fraction after drug treatment was cal-
culated as:
SF = N,/N2 (5a)
where N, and N2 are the number of cells after irradiation
plus drug treatment and after irradiation alone, respectively.
s.e.(SF) = SF [s.e.(N1)2/N12 + s.e.(N2)2/N22]1"2 (5b)
Equations lb to 5b should be considered approximative and
will only be valid if the coefficient of variation, that is the
ratio between the standard error and the parameter estimate,
is small. Simulation studies showed that equations lb and 2b
would produce reasonable standard error estimates, typically
within 10% of the empirical standard deviation, provided
that the s.e. of the TCD50 was <1.5 Gy with a TCD50 at
50Gy.
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